{"id":370020,"date":"2025-09-06T06:46:09","date_gmt":"2025-09-06T06:46:09","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/370020\/"},"modified":"2025-09-06T06:46:09","modified_gmt":"2025-09-06T06:46:09","slug":"le-vaccin-contre-le-vrs-efficace-pendant-deux-ans-chez-les-personnes-agees","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/370020\/","title":{"rendered":"Le vaccin contre le VRS efficace pendant deux ans chez les personnes \u00e2g\u00e9es"},"content":{"rendered":"<p>    Les deux vaccins prot\u00e9iques contre le VRS ont fait la preuve de leur efficacit\u00e9 pour les personnes de plus de 60 ans.<br \/>\n                RFBSIP \/ stock.adobe.com<\/p>\n<p>Cet outil de pr\u00e9vention contre des infections respiratoires parfois graves n\u2019est toujours pas rembours\u00e9 en France, regrettent les m\u00e9decins.<\/p>\n<p class=\"fig-paragraph\">Connu pour le risque de\u00a0<a href=\"http:\/\/www.lefigaro.fr\/societes\/les-vaccins-de-pfizer-et-sanofi-contre-la-bronchiolite-arrivent-en-pharmacie-20240830\" data-fig-type=\"Article\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"LEFIGARO\" target=\"_blank\" rel=\"noopener\">bronchiolite<\/a>\u00a0qu\u2019il fait courir aux nourrissons, le virus respiratoire syncytial (VRS) est aussi \u00e0 l\u2019origine de pneumonies graves et de d\u00e9compensations cardiaques chez les personnes \u00e2g\u00e9es ou fragiles. Pr\u00e8s de 12\u00a0000 hospitalisations lui ont \u00e9t\u00e9 attribu\u00e9es durant\u00a0<a href=\"http:\/\/www.lefigaro.fr\/demain\/sante\/l-epidemie-de-bronchiolite-gagne-trois-nouvelles-regions-de-france-20231018\" data-fig-type=\"NewsFlash\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"LEFIGARO\" target=\"_blank\" rel=\"noopener\">l\u2019\u00e9pid\u00e9mie hivernale<\/a>\u00a0de 2022-2023. Deux vaccins commercialis\u00e9s aux \u00c9tats-Unis en 2023, Arexvy et Abrysvo, peuvent cependant changer la donne. D\u00e9velopp\u00e9s par les laboratoires GSK et Pfizer, ils sont fabriqu\u00e9s \u00e0 partir d\u2019une prot\u00e9ine du virus, et ont montr\u00e9 leur potentiel dans la pr\u00e9vention des hospitalisations chez les sujets \u00e2g\u00e9s. Un troisi\u00e8me vaccin \u00e0 ARNm, d\u00e9velopp\u00e9 par Moderna, le mRESVIA, a \u00e9t\u00e9 mis sur le march\u00e9 plus r\u00e9cemment.<\/p>\n<p class=\"fig-paragraph\">Une \u00e9tude am\u00e9ricaine\u00a0<a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2838490?guestAccessKey=63e8c960-f2a9-4715-b0b4-3eef3da4189f&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jama&amp;utm_content=olf-tfl_&amp;utm_term=083025\" target=\"_blank\" rel=\"sponsored noopener\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\">publi\u00e9e dans la revue JAMA<\/a> \u00a0le 30 ao\u00fbt dernier confirme la protection conf\u00e9r\u00e9e par les deux vaccins prot\u00e9iques. Pour cette recherche, plus de 7\u00a0000 participants ont \u00e9t\u00e9 suivis sur deux ans, dans six h\u00f4pitaux et vingt \u00c9tats am\u00e9ricains. Ses r\u00e9sultats mettent en\u2026<\/p>\n<p class=\"fig-premium-paywall__infos\">\n        Cet article est r\u00e9serv\u00e9 aux abonn\u00e9s.        Il vous reste 80% \u00e0 d\u00e9couvrir.\n    <\/p>\n<p>                <img  data- alt=\"Le Figaro\" class=\"fig-img--complete fig-img\"\/><\/p>\n<p class=\"fig-premium-paywall__title\">Vente Flash<\/p>\n<p class=\"fig-premium-paywall__subtitle\">4,99\u20ac par mois pendant 12 mois. Sans engagement<\/p>\n<p class=\"fig-premium-paywall__connect\">\n                D\u00e9j\u00e0 abonn\u00e9\u00a0?                <a class=\"fig-premium-paywall__connect-link\" href=\"https:\/\/connect.lefigaro.fr\/login?client=sante_web&amp;type=main&amp;redirect_uri=https%3A%2F%2Fsante.lefigaro.fr%2Fsocial%2Fsante-publique%2Fle-vaccin-contre-le-vrs-efficace-pendant-deux-ans-chez-les-personnes-agees-20250906\" data-js-gtm=\"{&quot;customCategorie&quot;: &quot;conversion&quot;, &quot;customAction&quot;: &quot;before_Landing_Connexion_paywall_auto&quot;, &quot;customLabel&quot;: &quot;c2FudGUubGVmaWdhcm8uZnJfXzFmMDhhNWMyLTZjMmUtNmFmOC04OTIwLWQxZTM3NDhiNzRjMl9fQXJ0aWNsZQ==_Le vaccin contre le VRS efficace pendant deux ans chez les personnes \u00e2g\u00e9es_279&quot;, &quot;customIDSPE&quot;: &quot;c2FudGUubGVmaWdhcm8uZnJfXzFmMDhhNWMyLTZjMmUtNmFmOC04OTIwLWQxZTM3NDhiNzRjMl9fQXJ0aWNsZQ==&quot;, &quot;event&quot;: &quot;customEventSPE&quot;}\" target=\"_blank\" rel=\"noopener\"><br \/>\n                    Connectez-vous<br \/>\n                <\/a>\n            <\/p>\n","protected":false},"excerpt":{"rendered":"Les deux vaccins prot\u00e9iques contre le VRS ont fait la preuve de leur efficacit\u00e9 pour les personnes de&hellip;\n","protected":false},"author":2,"featured_media":370021,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[1011,27,72,26459,71,773],"class_list":{"0":"post-370020","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sante","8":"tag-fr","9":"tag-france","10":"tag-health","11":"tag-pneumonie","12":"tag-sante","13":"tag-vaccin"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115156011368331527","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/370020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=370020"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/370020\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/370021"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=370020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=370020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=370020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}